Abstract
Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) assessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. Studies results showed that negative results of these parameters after 3 to 6 months of therapy, identify a group of patients at low-risk for recurrent thrombosis in whom VKA treatment can be withheld. In the present review we will discuss advantages and potential limits of using these individual markers for the management of patients with a first episode of DVT of the lower limbs.
Keywords: DVT, residual vein thrombosis, D-Dimer, anticoagulation, Idiopathic Deep Vein Thrombosis, Venous Thrombo-Embolism, thrombosis, D-dimer (D-d) assay, Compression Ultra-Sonography, low-molecular weight-heparin, oral vitamin K an-tagonists, surgery, trauma, immobilization, cancer, paralysis, chronic diseases, warfarin therapy, pulmonary embolism, anticoagulant therapy, F2 G20210A (Prothrombin G20210A), F5 R506Q, Factor V Leiden, R506Q, thrombophilia, lupus anticoagulant, recent studies, antithrombotic treatment, recurrent venous thromboembolism, oral anticoagulation, low-intensity warfarin, Heterozygous Factor V Leiden, Prothrombin G20210A
Current Pharmaceutical Design
Title: Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis
Volume: 16 Issue: 31
Author(s): Alessandra Malato, Giorgia Saccullo, Alfonso Iorio, Walter Ageno and Sergio Siragusa
Affiliation:
Keywords: DVT, residual vein thrombosis, D-Dimer, anticoagulation, Idiopathic Deep Vein Thrombosis, Venous Thrombo-Embolism, thrombosis, D-dimer (D-d) assay, Compression Ultra-Sonography, low-molecular weight-heparin, oral vitamin K an-tagonists, surgery, trauma, immobilization, cancer, paralysis, chronic diseases, warfarin therapy, pulmonary embolism, anticoagulant therapy, F2 G20210A (Prothrombin G20210A), F5 R506Q, Factor V Leiden, R506Q, thrombophilia, lupus anticoagulant, recent studies, antithrombotic treatment, recurrent venous thromboembolism, oral anticoagulation, low-intensity warfarin, Heterozygous Factor V Leiden, Prothrombin G20210A
Abstract: Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) assessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. Studies results showed that negative results of these parameters after 3 to 6 months of therapy, identify a group of patients at low-risk for recurrent thrombosis in whom VKA treatment can be withheld. In the present review we will discuss advantages and potential limits of using these individual markers for the management of patients with a first episode of DVT of the lower limbs.
Export Options
About this article
Cite this article as:
Malato Alessandra, Saccullo Giorgia, Iorio Alfonso, Ageno Walter and Siragusa Sergio, Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563428
DOI https://dx.doi.org/10.2174/138161210793563428 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antithrombotic Therapy for Transcatheter Valvular Interventions: A Revisit
Current Vascular Pharmacology The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants
Cardiovascular & Hematological Disorders-Drug Targets Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure
Current Pharmaceutical Design From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Prostacyclin Synthase Gene: Genetic Polymorphisms and Prevention of Some Cardiovascular Diseases
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese
Current Drug Targets Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease?
Reviews on Recent Clinical Trials S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease
Current Pharmaceutical Design Leech Thrombin Inhibitors
Current Pharmaceutical Design Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Neurological Disorders in Pregnancy
Current Women`s Health Reviews Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)